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Abstract 
Background: The current study evaluated level of  serum asymmetric dimethylarginine (ADMA) and its association to cardiac 
biomarkers in thalassemia patients for early diagnosis of  abnormality in myocardial infarction. 
Subjects and methods: This study was conducted on 80 subjects divided into four groups each with 20 subjects. Group I: Con-
trol: healthy subjects. Group II: Myocardial infarction: Patients with elevated serum troponin T. Group III: thalassemia patients. 
Group IV: thalassemia with myocardial   infarction patients:  Included 20 thalassemia patients   with Myocardial   infarction. 
Serum samples were subjected for assay of  creatine kinase (CK:MB), Lactate dehydrogenase, troponin I ,ADMA,  Serum MDA 
level was  determined. 
Results: Data obtained showed that serum   CKMB, LDH1, AST, Troponin T and ADMA levels were significant elevated in 
MI with or without  Thalassemia  compared with control groups. Serum MDA was statistically significantly elevated in MI with 
or without Thalassemia compared with control groups. The serum level of  troponin T showed an area under curve (AUC) of  
0.92 ,(sensitivity 91.0 % and specificity, 88%). Also, the ADMA supported the diagnostic profile, showing an AUC of  0.85 with 
(sensitivity, 92.0%; specificity, 91,9%). 
Conclusion: Serum ADMA is sensitive marker for incidence of  MI in thalassemia patients.
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Introduction
Thalassemias are known genetically inherited blood disor-
ders, that can result in abnormal hemoglobin formation. 
Quite often, the individuals suffer from mild to severe 
anemia, yellowish skin, enlarged spleen, dark urine, bone 
problems and slow growth (among children)1. Mainly, 
there are two types of  thalassemias, the alpha thalassemia 
and the beta thalassemia; their severity is dependent upon 
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the number of  missing genes out of  four for alpha glo-
bin and two for beta globin1. In alpha thalassemia, genes 
HBA1 and HBA2 (on chromosome 16) are involved, of  
which, two gene loci are present, and therefore, four al-
leles exist.As a result of  alpha thalassemia, there is a de-
crease in the alpha-globin production, hence alpha-globin 
chains production is lowered, which in turn results in an 
excess of  beta chains among the adults and gamma chains 
in newborns. This excess of  beta chains produce tetram-
ers which are unstable (known as hemoglobin H or HbH 
of  4 beta chains), and show defective oxygen release. In 
beta thalassemia   there are mutations in the HBB gene 
(on chromosome 11), and the severity depends on the 
nature and on the presence of  mutations in one or both 
alleles. The clinical picture is described by the situation of  
both the alleles: β thalassemia major: caused by a β0/β0 
genotype, i.e., no functional β chains are formed, most se-
vere form of  β-thalassemia. Β thalassemia minor: caused 
by β/β0 or β/β+ genotypes. Here, mutation is present in 
one of  the two β globin alleles, therefore, the production 
of  β chain is not compromised.
Anemia and chronic ineffective erythropoiesis are the 
characteristics of  thalassemia major as its primary prob-
lems, so, certain physiological adaptations are produced 
in the cardiovascular system. People with chronic anemia 
have an increased cardiac output, so that the oxygen de-
livery is maintained. This results in increased heart rate 
and cardiac dimensions. Patients with chronic anemia 
have higher resting oxygen consumption and lower re-
serves. With increased resting metabolism, there is also an 
increase in oxidative stress.Hypersplenism is also found 
to be common among the people suffering from thal-
assemia. This condition may require and necessitate the 
removal of  spleen. In the removal of  hematologic de-
bris from cardiovascular system, spleen nevertheless has 
a critical function. Platelet fragments, RBC fragments, 
phosphatidylserine positive platelets are known strong 
pro-coagulants. Moreover, they inhibit nitric oxide (a 
powerful vasodilator) and stimulate substances that pro-
mote vasoconstriction, like: endothelin and prostaglan-
dins, and produce endothelial proliferation2. This implies 
that splenectomy (removal of  spleen), may carry a strong 
risk of  intra vascular thrombosis. Individuals suffering 
from thalassemia acquire excess of  iron because of  an in-
crease in absorption of  iron and transfusion therapy. Iron 
is known to be toxic to endocrine glands supporting the 
heart. Iron may poison thyroid and parathyroid glands, 
thereby affecting metabolism and calcium regulation.
Asymmetric dimethylarginine (ADMA) is a modified 
amino acid that occurs naturally in human blood, and 
is known to inhibit nitric oxide production. Nitric oxide 
plays a key role in vascular tone regulation, thereby has 
an important contribution in atherosclerosis3,4,5. Studies 
suggested that higher the values of  circulating ADMA 
level more are incidences of  cardiovascular disease 
(CVD). Studies carried out in mice with elevated ADMA 
levels (genetically and chemically) exhibited an increase in 
blood pressure and systemic vascular resistance6,7, on the 
other hand they showed a decrease in these parameters 
with low ADMA level8. In addition to this, high ADMA 
and low NO may result in vascular inflammation9, LDL 
oxidation10 endothelial cell apoptosis11 aggregation and 
adhesion of  platelets12. Thus, it could be said that ADMA 
and NO play a crucial role in endothelial dysfunction, 
which is the first step in atherogenesis, and hence ADMA 
may also be a risk factor for cardiovascular disease in thal-
assemia, in a way by inhibition of  nitric oxide. Troponin is 
a complex protein (consisting of  three proteins: troponin 
C, troponin I, and troponin T). Troponin is important in 
muscle contraction, both in skeletal and cardiac muscles. 
Troponin I holds actin-tropomyosin complex in place by 
binding to actin in thin myofilaments, due to which, in a 
relaxed muscle, myosin cannot bind with actin (letter I 
stands for inhibitory character). Troponin I is useful in 
laboratory diagnosis of  heart attack.
Due to iron overload, the first cause of  death among thal-
assemia major patients is iron induced cardiac dysfunc-
tion (abnormality of  pumping and conduction)13,14,15. It 
was reported that high ferritin (iron containing protein in 
blood) concentration is related to high troponin levels in 
patients who are receiving high  iron sucrose16. Iron ab-
sorption is enhanced by mutations in the hypophis-hypo-
thalamus axis in JAK STAT pathway17. Iron is reportedly 
deposited in the patients in parenchyma tissues, including 
the heart. This increase in iron levels results in free radical 
formation and lipid oxidation of  cardio-myocyte mem-
branes, eventually leading to damage18. During cell dam-
age, there is a loss of  myocyte contraction force resulting 
in the release of  troponin. Increase in troponin levels 
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can be considered a specific and a sensible biomarker for 
myocardial injury in the early stages and could be well 
referred as the beginning of  a microinfarct19.                                           
Additional experiments were performed by Yu Han et 
al20 in which using human umbilical vein endothelial cells 
(HUVECs) it was shown that the detrimental effect of  
troponin I (cardiac troponin I)was related to increase in 
VCAM 1expression (functions as a cell adhesion mole-
cule) induced by troponin I, and adhesion of  human 
monocytes THP-1(a human monocytic cell line derived 
from an acute monocytic leukemia patient) mediated by 
VCAM 1 to HUVECs, which could be neutralized by 
VCAM1 antibody. It was reported that NF-kB and toll-
like receptor 4 (TLR4), both had a role involved this sig-
naling pathway. This was inferred due to the fact that tro-
ponin I’s effect on VCAM 1 expression and adhesion of  
monocytes to the endothelial cells was inhibited if  there 
was any blockade of  either of  the two - TLR4 or NF-
kB. Furthermore, troponin I augmented cardiac injury 
in rats with myocardial ischemia- reperfusion injury was 
reduced after the inhibition of  TLR420. They concluded 
that troponin I aggravates myocardial ischemia- reperfu-
sion injury by induction adhesion of  monocytes to vascu-
lar endothelial cells by activating TLR4/NF-kB pathway. 
Thus, inhibiting of  TLR4 may prove to be an alternative 
strategy to reduce troponin I induced myocardial inju-
ry20.The rationale of  this study was to evaluate serum di-
methylarginine and its association to cardiac biomarkers 
in thalassemia patients for early diagnosis of  myocardial 
infarction  to avoid its complications.
Subjects and methods
Informed consent was taken from all individuals includ-
ed in this study. The study was done according to ethical 
committee of  King Abdulaziz University. This study was 
conducted on 80 subjects admitted to the Hematology 
Department, King Abdulaziz University. All individual 
were subjected to full clinical examination (diabetes, hy-
pertension, cardiovascular disorder). They were classified 
according to clinical examination to the following groups: 
Group I: Control group: Included 20 healthy subjects 
with no evidence for any symptoms of  clinical disorder. 
Group II: Myocardial infarction patients: Included 20 pa-
tients all patients of  this group were confirmed to have 
myocardial infarction by clinical examination and elevat-
ed serum troponine T.  Group III: Thalassemia patients: 
Included 20 patients who were graded according to blood 
picture , all patients of  this group were confirmed to have 
thalassemia by clinical examination and hematological pa-
rameters. Group IV: Thalassemia with myocardial infarc-
tion:  Included 20 thalassemia patients with myocardial 
infarction, all patients of  this group were confirmed by 
clinical examination and hematological parameters.  Ex-
clusion criteria included, liver disease, renal dysfunction, 
hyperplasia and diabetes.  
Sample collection
A five ml blood sample was collected from each subject. 
Serum was separated by centrifugation at 4000 r.p.m for 
10 minutes.  Serum was stored at –80°C until used.Se-
rum samples were subjected to the following examina-
tion. Creatine kinase (CK2:MB), Lactate dehydrogenase 
(LDH1), Serum Aspartate transaminase, Serum troponin 
I, by kits from BioLab, Jeddah.
Assay of  asymmetric dimethylarginine (ADMA).
Serum ADMA was measured by HPLC15. N-monometh-
yl L-arginine (NMMA) was used as the internal standard 
. Serum ADMA  was extracted by  (NH3 /1M NaOH/ 
waterCH3OH) (10/0.5/40/50; v/v/v/v) .The it was 
derivatized with ortho-phthaldialdehyde (OPA) reagent 
(1:1; v:v) and injected into the HPLC system, with a 
fluorescent detector. Chromatographic separation was 
performed isocratically at 100% mobile phase A, with 
25 mmol/L phosphate buffer (pH 6.8) containing 6.5% 
CH3CN, at a flow rate of  1.1 mL/min. Mobile phase 
was water:CH3CN (50:50, v:v), and the flow rate was in-
creased to 2.0 mL/min .
Statistical analysis
Statistical analysis will be done by SPSS using student's 
t-test. Value of  P < 0.05 was considered as statistically 
significant. ANOVA test was performed to correlate be-
tween different groups.
Results
Table (1) showed that serum   CKMB, LDH1, AST, Tro-
ponin T and ADMA levels were significantly elevated in 
MI with or without Thalassemia  compared with control 
groups (p<0.001) for each. Serum malondialdhyde was 
statistically significantly elevated in MI with or without 
Thalassemia compared with control groups (p<0.001). 
ANOVA analysis showed non-significant changes ob-
served between MI and MI with Thalassemia. Non-sig-
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nificant changes in the levels of  hemoglobin in MI 
compared with control but it was significantly reduced 
in thalassemia with or without MI. Serum MDA was sig-
nificantly  increased in MI with or without  Thalassemia 
(P < 0.001, p<0.001) .The level of  serum ADMA lev-
el was positively correlated with increase in troponin T 
(P < 0.01). The cut-off  value in 90% patients at the MI 
with or without  Thalassemia 70%. Positive correlations 
were observed between troponin (r=0.66), and ADMA 
(r=0.73) while there was no correlation with other labo-
ratory markers such as plasma AST and LDH.
Table (1). The levels of hemoglobin, activities of serum CK;MB, LDH1 and AST  in All 
studied groups (mean  ±SD). 


































































































































n = number of cases p1value, thalassemia, Myocardial infarction and thalassemia with Myocardial infarction versus 
control.   p2 value , thalassemia with Myocardial infarction versus Myocardial infarction 
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Table (2). The levels of serum troponin T, ADMA and MDA in all studied groups 
(mean ±SD) 
 
































































































n = number of cases p1value, thalassemia, Myocardial infarction and thalassemia with Myocardial infarction versus 
control.   p2 value , thalassemia with Myocardial infarction versus Myocardial infarction 
 
Table 3. Receiver operating curve (ROC)  analysis of investigated  urine parameters  
asa test for diagnosis of diabetic nephropathy 
 
 Variable                                  ADMA         TropT                                 CK:MB                          
AUC                                           0.91                 0.78                                    0.95 
Sensitivity (%)                         89 %             92.3%                                 95.5%   
Specificity (%)                         90.4%            89.9%                                 97%          
AUC; area under curve Receiver operating curve (ROC) analysis   were performed to define the diagnostic profile 
markers among subjects with MI. The serum level of troponin T showed an area under curve (AUC) of 0.92 with 
(sensitivity 91.0 % and  specificity, 88%). Also, the ADMA supported the diagnostic profile, showing an AUC of 
0.85 with (sensitivity, 92.0%; specificity, 91,9%). 
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Discussion
Contributing to the correct orientation  in the therapeutic 
protocol in management of  early myocardial infarction 
in thalassemia subjects to avoid complications of  chronic 
cardiac dysfunctions, we designed a prospective study to 
assess the association between plasma ADMA level and 
incidence of  MI in  patients with thalessemia.
Data obtained showed that, serum troponin T was signifi-
cantly elevated in pateints with MI and thalassemia cases, 
but In MI it was higher statistically (p<0.001). This is in-
724
dicated that, troponin T was released from muscle heart 
as a result of  heart injury. This is was more sensitive test 
than myoglobin12.
It was found that in this study, serum ADMA was signifi-
cantly elevated in MI and thalassemia and MI with thal-
assemia patents compared with control group (p<0.01, 
0.001 and 0.01) respectively. Serum ADMA is a well-char-
acterized circulating endogenous inhibitor of  NO syn-
thase6,7, and may compete with L-arginine as the substrate 
for NO synthase which can lead to decreases in both the 
production and availability of  endothelium-derived NO8. 
Elevated plasma ADMA level has been associated with 
MI7,9 and was observed in patients with various risk fac-
tors for atherosclerosis10,11. Several studies have shown 
that plasma ADMA level may predict the progression of  
renal injury in patients with early-stage MI15,16.
 
Since NO normally inhibits platelet aggregation and ad-
hesion14,16, any decrease in NO levels may trigger throm-
bus formation and development on a ruptured plaque. It 
is documented that NO generated from activated plate-
lets inhibits further platelet recruitment to the developing 
thrombus17. This is recommended by elevation of  cardiac 
markers CKMB and LDH1 and troponin T25.
 
High ADMA levels are also associated with elevated car-
diac output30, mechanisms that may well be incriminated 
in the morning occurrence of  myocardial infarction6–11.
However, previous  studies that investigated the troponin 
in MI found that it was correlated with ADMA level33.
It was stated that, ADMA was elevated in MI with or 
without thalassemia but the elevation  in thalassemia was 
higher than without.
AUC; area under curve Receiver operating curve (ROC) 
analysis  was performed to define the diagnostic profile 
markers among subjects with MI. The serum level of  
troponin T showed an area under curve (AUC) of  0.92 
with (sensitivity 91.0 % and  specificity, 88%). Also, the 
ADMA supported the diagnostic profile, showing an 
AUC of  0.85 with (sensitivity, 92.0%; specificity, 91,9%).
Conclusion
Assessment of  serum ADMA in combination with oth-
er routine tests (LDH1, CKMB) and cardiac troponin T 
may give good prediction for early diagnosis of  MI in 
patients with thalassemia.
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